BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

BioRestorative Therapies announced completion of dosing in its Phase 2 clinical trial for BRTX-100, treating 99 patients with chronic lumbar disc disease. The randomized, double-blind, sham-controlled study has advanced to blinded follow-up with topline safety and efficacy data expected in Q2 2027. The company received FDA alignment on Phase 3 development pathway following a Type B meeting, with no clinical safety concerns raised.

05/26/2026, 11:00 AM • GlobeNewswire

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

BioRestorative Therapies presented preclinical data at ISCT 2026 demonstrating that extracellular vesicles derived from different mesenchymal stem cell sources exhibit distinct protein signatures and functional properties. The findings support development of targeted exosome-based formulations for regenerative and aesthetic applications, with implications for the company's BioCosmeceutical platform spanning skin rejuvenation, wound repair, and hair health applications.

05/13/2026, 11:00 AM • GlobeNewswire

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

BioRestorative Therapies will participate in the Be+Well Beauty and Wellness Show (March 8-10, 2026) to expand commercialization of its BioCosmeceutical platform. The company's commercial leadership team will engage with industry partners and distributors to discuss product adoption and deployment of regenerative skincare technologies. BioRestorative positions itself as a differentiated biotech player in the emerging regenerative aesthetics market, leveraging its cGMP-compliant manufacturing and scientific infrastructure.

03/05/2026, 8:00 AM • GlobeNewswire

BioRestorative Announces Closing of $5.0 Million Public Offering

BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced the closing of a public offering of 14,285,715 shares and accompanying warrants at $0.35 per share, raising approximately $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100 (a stem cell therapy for disc/spine disease), pre-clinical research on its ThermoStem Program (for metabolic disorders), development of its commercial biocosmeceuticals platform, and general corporate purposes.

02/13/2026, 8:30 PM • GlobeNewswire

BioRestorative Announces Pricing of $5.0 Million Public Offering

BioRestorative Therapies (NASDAQ:BRTX) announced the pricing of a public offering of approximately 14.3 million shares and warrants at $0.35 per share, expected to raise $5.0 million in gross proceeds. The company plans to use the funds for clinical trials of BRTX-100, pre-clinical research for its ThermoStem Program, development of its biocosmeceuticals platform, and general corporate purposes.

02/11/2026, 10:30 PM • GlobeNewswire

Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight

DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.

01/28/2026, 1:00 PM • GlobeNewswire

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

BioRestorative Therapies has been granted a Type B meeting with the FDA to discuss an accelerated Biologics License Application approval pathway for BRTX-100, a stem cell-based treatment for chronic lumbar disc disease, with plans to request an expedited Phase 3 trial timeline.

11/17/2025, 7:00 AM • GlobeNewswire